Abiopharma

WISeKey and SEALSQ Welcome White House Executive Order on Quantum Security, Highlighting the Critical Three-Year Window to Prepare Society for Q-Day

Change – Announcement of Appointment::Appointment of Executive Director and Group Chief Executive Officer – Ong Choon Yi (Wang Junyi)

Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s)::Cessation of Substantial Shareholder – Yee Pinh Jeremy

Silexion Therapeutics Receives Approval from Germanys BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s)::Cessation of Substantial Shareholder – Chen Johnson

Interested Person Transaction: Revision of Annual Caps

Backblaze Announces Five-Year Multi-Exabyte Data Storage Agreement with CoreWeave

Clinical trial NCT05297773 updates: 1. status: RECRUITING → COMPLETED 2. enrollment type: ESTIMATED → ACTUAL 3. collaborators added: Faculdade de Motricidade Humana 4. collaborators removed: Faculdade de Motricidade Humana - Universidade de Lisboa

Clinical trial NCT07644559: start date: 2026-06-01 → 2026-06-16.

Clinical trial NCT05367505 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. completion date: 2026-12-01 → 2028-02-07 3. primary completion date: 2026-12-01 → 2027-06-07 4. enrollment: 60 → 50 participants 5. enrollment type: ESTIMATED → ACTUAL